HINGHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq:MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY® Robotic System, the first disposable robotic system being developed for endovascular procedures. The study was performed by a team of seasoned Key Opinion Leaders (KOLs) in the endovascular space at a world-class MedTech research laboratory with FDA-required levels of planning, controlling, monitoring, and reporting (GLP standards), using porcine model.

Read more at globenewswire.com

Related news for (MBOT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.